Genome-scale CRISPR screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma [CRISPR sgRNA]

Myc dysregulation underpins lymphomagenesis in the Atm-null DLBCL model and confers dependence on nucleotide biosynthesis.MYC-driven DLBCL is sensitive to nucleotide depletion with combined mycophenolate mofetil and adavosertib in vitro and in vivo. A genome-scale CRISPR Cas9 dropout screen was performed on B-cells cell lines generated from ATM-null DLBCL cells using Mouse CRISPR Knockout Pooled Library (GeCKO v2)